Compare FL, TMR X and other specific dye models. Choose NHS ester, maleimide, azide or DBCO for conjugation, or preconjugated WGA for glycan recognition.
40 products
Match FL, TMR X or the exact numbered model to the source, filters and chemistry; check solubility after aqueous dilution. WGA probes recognize glycans. The BODIPY name alone does not make these reactive dyes lipid-droplet or lipid-peroxidation probes.
Showing 1–24 of 40 products
| Product / Cat. No. | Product form | Excitation / nm | Emission / nm | Pack sizes | Product details |
|---|---|---|---|---|---|
| BODIPY FL Succinimidyl EsterQH-40-4004 | NHS Ester | 502 | 510 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY FL MaleimideQH-40-4004(Maleimide) | Maleimide | 502 | 510 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY FL AzideQH-40-4004(Azide) | Azide | 502 | 510 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY FL DBCOQH-40-4004(DBCO) | DBCO | 502 | 510 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY FL WGAQH-40-4004(WGA) | WGA | 502 | 510 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY530/550 Succinimidyl EsterQH-40-4005 | NHS Ester | 534 | 551 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY530/550 MaleimideQH-40-4005(Maleimide) | Maleimide | 534 | 551 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY530/550 AzideQH-40-4005(Azide) | Azide | 534 | 551 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 530/550 DBCOQH-40-4005(DBCO) | DBCO | 534 | 551 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 530/550 WGAQH-40-4005(WGA) | WGA | 534 | 551 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY TMR X NHS EsterQH-40-4008 | NHS Ester | 544 | 570 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY TMR X MaleimideQH-40-4008(Maleimide) | Maleimide | 544 | 570 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY TMR X AzideQH-40-4008(Azide) | Azide | 544 | 570 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY TMR X DBCOQH-40-4008(DBCO) | DBCO | 544 | 570 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY TMR X WGAQH-40-4008(WGA) | WGA | 544 | 570 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY558/568 Succinimidyl EsterQH-40-4002 | NHS Ester | 559 | 568 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY558/568 MaleimideQH-40-4002(Maleimide) | Maleimide | 559 | 568 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY558/568 AzideQH-40-4002(Azide) | Azide | 559 | 568 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 558/568 DBCOQH-40-4002(DBCO) | DBCO | 559 | 568 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 558/568 WGAQH-40-4002(WGA) | WGA | 559 | 568 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY564/570 Succinimidyl EsterQH-40-4003 | NHS Ester | 565 | 574 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY564/570 MaleimideQH-40-4003(Maleimide) | Maleimide | 565 | 574 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY564/570 AzideQH-40-4003(Azide) | Azide | 565 | 574 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 564/570 DBCOQH-40-4003(DBCO) | DBCO | 565 | 574 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 564/570 WGAQH-40-4003(WGA) | WGA | 565 | 574 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY576/589 Succinimidyl EsterQH-40-4001 | NHS Ester | 575 | 588 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY576/589 MaleimideQH-40-4001(Maleimide) | Maleimide | 575 | 588 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY576/589 AzideQH-40-4001(Azide) | Azide | 575 | 588 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 576/589 DBCOQH-40-4001(DBCO) | DBCO | 575 | 588 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 576/589 WGAQH-40-4001(WGA) | WGA | 575 | 588 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY581/591 Succinimidyl EsterQH-40-4006 | NHS Ester | 581 | 591 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY581/591 MaleimideQH-40-4006(Maleimide) | Maleimide | 581 | 591 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY581/591 AzideQH-40-4006(Azide) | Azide | 581 | 591 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 581/591 DBCOQH-40-4006(DBCO) | DBCO | 581 | 591 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 581/591 WGAQH-40-4006(WGA) | WGA | 581 | 591 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 650-665-X Succinimidyl EsterQH-40-4007 | NHS Ester | 646 | 660 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 650-665-X MaleimideQH-40-4007(Maleimide) | Maleimide | 646 | 660 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 650-665-X AzideQH-40-4007(Azide) | Azide | 646 | 660 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 650-665-X DBCOQH-40-4007(DBCO) | DBCO | 646 | 660 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg | |
| BODIPY 650-665-X WGAQH-40-4007(WGA) | WGA | 646 | 660 | 1 mg / 5 mg / 10 mg / 25 mg / 100 mg |
For support, include: Molecule to label or glycan-recognition task, sample formulation and detection channel
BODIPY structure, spacer and sample environment affect formulation and fluorescence. Check FL, TMR X and numbered models separately rather than assuming one preparation method.
Method background: BODIPY dye series · Molecular Probes Handbook ↗
The WGA products are fluorescent lectin probes whose detection depends on glycan recognition. Handle the protein formulation separately from reactive dye stocks.
Tris and glycine consume NHS dye. BSA and gelatin require separation from the target protein; routine buffer exchange is insufficient.
Applies to: For protein preparation before NHS-ester labeling; check competing amines and carrier proteins.
Calculate DOL with absorbance correction, distinguish input ratio from attached dye, and assess recovery and binding.
Applies to: For purified protein conjugates; use this dye’s absorbance parameters and distinguish input ratio from DOL.
Cysteines may be disulfide-bound or protected. Confirm free thiols before deciding on reduction.
Applies to: For maleimide reactive dyes; first establish accessible thiols on the sample.
DTT and β-mercaptoethanol compete for maleimide; residual TCEP can also interfere.
Applies to: For maleimide routes; assess reductant carryover and removal.
Use CuAAC for terminal alkynes and SPAAC for strained alkynes. Identify the handle before assessing copper compatibility.
Applies to: For azide reactive dyes; distinguish terminal from strained alkynes before choosing CuAAC or SPAAC.
Target-bound azides enable coupling; free azide reagents and sodium azide can compete for DBCO.
Applies to: For the SPAAC step between DBCO and a target azide; ordinary amines and thiols are not reaction partners.
WGA labels accessible glycans. Check outline continuity for segmentation; intensity is not a direct measure of membrane amount.
Applies to: For WGA conjugates; glycan accessibility and membrane outlines do not establish protein-specific targeting.
Fixation and permeabilization can change glycan accessibility. Compare outlines, intracellular signal and background separately.
Applies to: For comparing fixation and permeabilization with WGA probes, not for free-dye conjugation.
These papers and manufacturer methods are selected for the current product use. Their reagents, conditions and parameters belong to the reported systems, not to measured Qihe product performance or universal operating conditions.
Loudet A, Burgess K. · Chemical Reviews · 107(11):4891–4932 · 2007
Reviews BODIPY synthesis, derivatization and spectroscopic properties as background for distinguishing members of the dye family.
DOI: 10.1021/cr078381n
Nanda JS, Lorsch JR. · Methods in Enzymology · 536:87–94 · 2014
Uses FAM ester labeling of a protein to explain primary-amine chemistry and labeling-efficiency assessment. It informs NHS workflow design; input and reaction conditions depend on the actual dye and sample.
Vira S, Mekhedov E, Humphrey G, Blank PS. · Analytical Biochemistry · 402(2):146–150 · 2010
Uses FITC-labeled anti-HA antibody to assess changes in labeling density and antigen binding. It informs input-series design and post-purification functional testing; DOL alone is insufficient for selecting a conjugate.
Ksenofontova KV, Kerner AA, Ksenofontov AA, et al. · Molecules · 27(22):7911 · 2022
Studies solvent and protein-conjugation effects on NHS-Ph-BODIPY spectra, informing evaluation of a conjugate in its final sample environment.
Shafer DE, Inman JK, Lees A. · Analytical Biochemistry · 282(1):161–164 · 2000
Examines TCEP interactions with reactive groups, informing evaluation of reductant carryover and buffer exchange.
Baldwin AD, Kiick KL. · Bioconjugate Chemistry · 22(10):1946–1953 · 2011
Studies exchange reactions of model adducts in thiol-containing environments to inform conjugate stability assessment.
DOI: 10.1021/bc200148v
Presolski SI, Hong VP, Finn MG. · Current Protocols in Chemical Biology · 3(4):153–162 · 2011
Describes CuAAC catalyst systems and reaction assessment for terminal-alkyne substrates.
Agard NJ, Prescher JA, Bertozzi CR. · Journal of the American Chemical Society · 126(46):15046–15047 · 2004
Introduces ring-strain-driven azide–alkyne coupling without copper, a foundational study in SPAAC bioconjugation.
DOI: 10.1021/ja044996f
Debets MF, van Berkel SS, Schoffelen S, et al. · Chemical Communications · 46(1):97–99 · 2010
Reports copper-free reaction of a strained alkyne with azides and its application to enzyme PEGylation.
DOI: 10.1039/b917797c
Chazotte B. · Cold Spring Harbor Protocols · 2011(5):pdb.prot5623 · 2011
Describes glycan-dependent membrane labeling with WGA, informing sample preparation and imaging design.
DOI: 10.1101/pdb.prot5623
Select a catalog number and the information you need, then enter your phone and email for a reply. Include the vial lot number for a CoA.
Choose a product above to enable the request buttons.
Product use, preparation, operating conditions and storage.
Spectra, measurement conditions and detection settings for the exact catalog number.
Lot-specific test results. Include the lot number from the vial.
Handling, storage and emergency response information.
BODIPY names a fluorophore class; substituents and conjugation partners determine use. These reactive forms support covalent labeling, while WGA recognizes glycans. The family name does not establish the function of a specialized lipid probe.
Stock dissolution does not establish aqueous compatibility. Check the exact model’s final solvent fraction, concentration, adsorption and aggregation in a small dilution test. Match solvent controls and assess the conjugate after purification.
Configure each model from its peaks and passbands. Many BODIPY dyes have closely spaced excitation and emission; check excitation rejection so leakage or scatter is not mistaken for fluorescence enhancement. Assess multicolor combinations with actual single stains.
Match NHS ester, maleimide, azide and DBCO to the appropriate amine, thiol or click handle. Confirm stock solvent, sample additives and reaction conditions for that form rather than retaining another reactive end’s recipe.
WGA is already fluorescently conjugated. Follow its supported aqueous protein formulation, define live/fixed/permeabilized conditions and titrate staining concentration and time. Design separate surface-glycan and uptake controls rather than using a free-dye preparation.
We use cookies and third-party analytics (Microsoft Clarity, Baidu Tongji, Google Analytics) to measure traffic and improve our service. Clarity includes session recording. You may decline — core site functionality is unaffected. View privacy policy
